Abstract
4-Aminopyridine (4AP) potentiates acetylcholine (ACh) release by blocking potassium channel in axon terminal and can be used in the treatment of Alzheimer’s type of dementia and cognitive disorder. It is reported that ACh is well related with memory and learning. On the basis of these fact, we decided to synthesis and evaluate some new Schiff bases of 4AP (SBAPs) for their putative cognition enhancing, antiamnesic, and anticholinesterase activity. The synthesized and purified SBAPs were characterized by elemental analysis, UV, FTIR, 1H-, and 13C-NMR. SBAPs facilitated the learning on elevated plus maze model and they also significantly reversed the scopolamine-induced amnesia on the same model. The effect of SBAPs on learning and memory was qualitatively similar to standard nootropic drug piracetam used. The SBAPs were found to inhibit acetylcholinesterase enzyme significantly in specific brain regions prefrontal cortex, hippocampus, and hypothalamus. Thus, SBAPs derivatives showed cognitive and antiamnesic activities in the model tested and these effects may probably be due to their anticholinesterase activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andreani A, Leoni A, Locatelli A, Morigi R, Rambaldi M, Pietra C, Villetti G (2000) 4-Aminopyridine derivatives with antiamnesic activity. Eur J Med Chem 35:77–82
Bartus RT, Dean RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–414
Belluti F, Piazzi L, Bisi A, Gobbi S, Bartolini M, Cavalli A, Valenti P, Rampa A (2009) Design, synthesis and evaluation of benzophenone derivatives as novel acetylcholinesterase inhibitors. Eur J Med Chem 44:1341–1348
Belluti F, Bartolini M, Bottegoni G, Bisi A, Cavalli A, Andrisano V, Rampa A (2011) Benzophenone-based derivatives: a novel series of potent and selective dual inhibitors of acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. Eur J Med Chem 46:1682–1693
Cavallito CJ, Yun HS, Edwards ML, Foldes FF (1971) Choline acetyltransferase inhibitors. Styrylpyridine analogs with nitrogen-atom modifications. J Med Chem 14:130–133
Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 25:1403
Dhingra D, Parle M, Kulkarni SK (2004) Memory enhancing activity of glycyrrhiza glabra in mice. J Ethnopharmacol 91:361–365
Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95
Folgering H, Rutten J, Agoston S (1979) Stimulation of phrenic nerve activity by an acetylcholine releasing drug: 4-Aminopyridine. Pflugers Arch 379:181–185
Galisteo M, Rissel M, Sergent O, Chevanne M, Cillard J, Guillouzo A, Lagadic-Gossmann D (2000) Hepatotoxicity of tacrine: occurrence of membrane fluidity alterations without involvement of lipid peroxidation. J Pharmacol Exp Ther 294:160–167
Giacobini E (2001) Is anti-cholinesterase therapy of Alzheimer’s disease delaying progression? Aging (Milano) 13:247–254
Giovannini MG, Casamenti F, Bartolini L, Pepeu G (1997) The brain cholinergic system as a target of cognition enhancers. Behav Brain Res 83:1–5
Glover WE (1982) The aminopyridines. Gen Pharmacal 13:259–285
Glowinski J, Iversen LL (1966) Regional studies of catecholamines in the rat brain. I. The disposition of [3H] norepinephrine, [3H] dopamine and [3H] dopa in various regions of the brain. J Neurochem 13:655–669
Grossberg GT, Stahelin HB, Messina JC, Anand R, Veach J (2000) Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriatr Psychiatry 15:242–247
Gualtieri F, Manetti D, Romanelli MN, Ghelardini C (2002) Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Des 8:125–138
Hakansson L (2009) Mechanism of action of cholinesterase inhibitors in Alzheimer’s disease. Acta Neurol Scand 88:7–9
Harley CW, Lacaille JC, Galway M (1983) Hypothalamic afferents to the dorsal dentate gyrus contain acetylcholinesterase. Brain Res 270:335–339
Itoh J, Nabeshima T, Kameyama T (1990) Utility of an elevated plus maze for the evaluation of memory in mice: Effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacology (Berl) 101:27–33
Knowlton BJ, Fanselow MS (1998) The hippocampus, consolidation and online memory. Curr Opin Neurobiol 8:293–296
Kumar V, Singh PN, Bhattacharya SK (2000) Effect of Indian Hypericum perforatum Linn on animal models of cognitive dysfunction. J Ethnopharmacol 72:119–128
Lahiri DK, Farlow MR, Greig NH, Sambamurti K (2002) Current drug targets for Alzheimer’s disease treatment. Drug Dev Res 56:267–281
Lowry OH, Rosebrough NJ, Farr AL, Rendall RJ (1951) Protein measurement with Folin phenol reagent. J Biol Chem 193:265–275
Milner PM (1991) Brain-stimulation reward: a review. Can J Psychol 45:1–36
Murray NMF, Newsome-Davis J (1981) Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 31:265–271
Pandey S, Srivastava RS (2010) Synthesis and characterization of some heterocyclic Schiff bases: potential anticonvulsant agents. Med Chem Res 20:1091–1101
Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977) Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34:247–265
Polman CH, Bertelsmann FW, van Loenen AC, Koeteier JC (1994) 4-aminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 51:292–296
Rakesh Ojha, Alakh NS, Muruganandam AV, Gireesh KS, Sairam K (2010) Asparagus recemosus enhances memory and protects against amnesia in rodent models. Brain Cogn 74:1–9
Scipione L, De Vita D, Musella A, Flammini L, Bertoni S, Barocelli E (2008) 4-Aminopyridine derivatives with anticholinesterase and antiamnesic activity. Bioorg Med Chem Lett 18:309–312
Sharma AC, Kulkarni SK (1992) Evaluation of learning and memory mechanisms employing elevated plus-maze in rats and mice. Prog Neuropsychopharmacol Biol Psychiatry 16:117–125
Singh GK, Garabadu D, Muruganandam AV, Joshi VK, Krishnamurthy S (2009) Antidepressant activity of Asparagus recemosus in rodent models. Pharmacol Biochem Behav 91:283–290
Solari A, Uitdehaag BMJ, Giuliani G, Pucci E, Taus C (2001) Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev (4): CD001330
Soriano-Mas C, Redolar-Ripoll D, Aldavert-Vera L, Morgado-Bernal I, Segura-Torres P (2005) Post-training intracranial self-stimulation facilitates a hippocampus-dependent task. Behav Brain Res 160:141–147
Squire LR, Zola-Morgan S (1991) The medial temporal lobe memory system. Science 253:1380–1386
Stork CM, Hoffman RS (1994) Characterization of 4-aminopyradine in overdose. J Toxicol Clin Toxicol 32:583–587
Taylor P (2001) Anticholinesterase agents. In: Hardman JG, Limbird LE (eds) The pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, p 175
Tronel S, Matthijs GPF, Susan JS (2004) Noradrenergic action in prefrontal cortex in the late stage of memory consolidation. Learn Mem 11:453–458
Yamada N, Hattori A, Hayashi T, Nishikawa T, Fukuda H, Fujino T (2004) Improvement of scopolamine-induced memory impairment by Z-ajoene in the water maze in mice. Pharmacol Biochem Behav 78:787–791
Acknowledgment
The authors gratefully acknowledge the University Grants Commission (UGC), New Delhi, India for the financial support to Mr. Saurabh K. Sinha (Grant no. R/Dev./IX-Sch./(SRF-JRF) Pharm./15402).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sinha, S.K., Shrivastava, S.K. Synthesis and evaluation of some new 4-aminopyridine derivatives as a potent antiamnesic and cognition enhancing drugs. Med Chem Res 21, 4395–4402 (2012). https://doi.org/10.1007/s00044-012-9982-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-012-9982-4